Targeting ETS Factor ERG as a Novel Therapeutic for the Treatment of Prostate Cancer

靶向 ETS 因子 ERG 作为治疗前列腺癌的新疗法

• 批准号: 327813
• 负责人: Roshan Moniri Mani
• 金额: $ 7.65万
• 依托单位: University of British Columbia
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2014
• 资助国家: 加拿大
• 起止时间: 2014-10-01 至 2017-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=327813&lang=en
• 关键词: Cancer Biology & Therapeutics; Molecular & Cellular Biology Of Cancer; Prostate Cancer; Therapeutic

Prostate cancer is one of the leading causes of cancer-related death in men worldwide. If diagnosed early, prostate cancer is curable by surgery and/or radiotherapy. In cases of locally advanced, recurrent, and metastatic disease, androgen deprivation th

前列腺癌是全世界男性癌症相关死亡的主要原因之一。如果早期诊断，前列腺癌可以通过手术和/或放疗治愈。 在局部晚期、复发性和转移性疾病的情况下，雄激素剥夺可能会导致局部晚期、复发性和转移性疾病。